Phospho-eIF4E stimulation facilitates HSV-1 early entry by regulating host factors and aggravates virus-induced oxidative damage

Viruses are masterful hijackers. They cannot make copies of themselves on their own; they must invade a living cell and commandeer its internal machinery to build new viral particles. One of the most critical tools a cell uses to build proteins is a molecular machine called the translation initiation complex. At the heart of this machine sits a specific protein, eIF4E, which acts like a gatekeeper, deciding which genetic instructions get translated into working proteins. In healthy cells, the activity of this gatekeeper is tightly controlled. However, many viruses have evolved to manipulate this control system, often by adding a chemical tag called a phosphate group to eIF4E. This modification, known as phosphorylation, usually boosts the cell's ability to produce proteins, a resource the virus then steals to fuel its own rapid reproduction. While scientists have long known that herpes simplex virus type 1 (HSV-1), the common cause of cold sores and potentially severe brain infections, uses this trick to help itself replicate later in an infection, the timing and purpose of this manipulation during the very first moments of infection remained a mystery.

A team of researchers set out to uncover what happens in the earliest hours after HSV-1 touches a cell. They discovered that the virus does not wait to hijack the cell's protein-making machinery; it triggers the phosphorylation of eIF4E almost immediately, within just one hour of infection. This rapid chemical change is not merely a side effect of the virus taking over; it is a deliberate strategy that helps the virus get inside the cell in the first place. By activating this specific pathway, the virus forces the cell to produce a small set of its own proteins—specifically ITGB2, CD63, and TSPAN3—which sit on the cell's surface. These proteins act as helpful handholds that the virus uses to attach and enter. When the researchers blocked the phosphorylation of eIF4E, either by using genetic mutations or by administering a drug that stops the process, the virus could not attach to the cell effectively, and its ability to infect was severely crippled.

The study went beyond the laboratory dish to see if this mechanism held true in a living organism. The researchers treated mice with a drug called eFT508, which inhibits the enzyme responsible for adding the phosphate tag to eIF4E. Mice that received this drug before being exposed to the virus showed significantly lower levels of the virus in their lungs and livers compared to untreated mice. More importantly, the drug protected the animals from the severe tissue damage and inflammation that typically accompanies a herpes infection. The treatment also helped restore the body's natural antioxidant defenses, which are often overwhelmed during a viral attack. These findings suggest that targeting the host cell's own translation machinery, rather than the virus itself, offers a promising new way to stop the infection before it can take hold and prevent the oxidative stress that leads to tissue damage.

The researchers arrived at these conclusions by carefully observing the behavior of the virus in different types of cells and under various conditions. They first established that in normal cells, the level of phosphorylated eIF4E spikes within the first hour of infection, a timing that coincides with the virus's entry phase. To prove that this spike was necessary for entry, they used a special line of cells where the eIF4E protein could not be phosphorylated. In these cells, the virus struggled to get inside, confirming that the chemical tag is essential for the initial invasion. They then identified the specific host proteins that were being produced in higher numbers because of this phosphorylation. By turning off the genes for ITGB2, CD63, and TSPAN3, they showed that the virus lost its ability to bind to the cell surface, proving that these proteins are the key targets the virus manipulates to gain entry.

In the animal experiments, the team administered the inhibitor eFT508 to mice at a dose of 30 milligrams per kilogram of body weight for two consecutive days before challenging them with the virus. The results were clear: the treated mice had much less virus in their tissues and suffered far less physical damage. The drug effectively reduced the swelling and cellular infiltration that characterize severe viral inflammation. It also reversed the drop in antioxidant enzymes like SOD, CAT, and GSH, which are crucial for neutralizing the harmful oxidative stress caused by the infection. The study indicates that while the virus has evolved to use the host's own signaling pathways to its advantage, interrupting this specific communication line can stop the infection at its earliest stage and mitigate the damage it causes. This approach highlights a potential strategy for developing antiviral treatments that target the host cell's response mechanisms, offering a way to combat the virus without relying on drugs that target the virus directly, which often lead to resistance.